Global Postmenopausal Osteoporosis Drugs Market Growth 2025-2031

October 2025 | 119 pages | ID: G7463E6784ACEN
LP Information

Abstracts

The global Postmenopausal Osteoporosis Drugs market size is predicted to grow from US$ million in 2025 to US$ million in 2031; it is expected to grow at a CAGR of %from 2025 to 2031.

The impact of the latest U.S. tariff measures and the corresponding policy responses from countries worldwide on market competitiveness, regional economic performance, and supply chain configurations will be comprehensively evaluated in this report.

Bones have the ability to grow and heal naturally, but changes in diet, exercise levels, and body chemistry lead to changes in the bone mineral density.

With the expected launch of promising pipeline molecules, the market for postmenopausal osteoporosis has a positive outlook in the coming years.

LP Information, Inc. (LPI) ' newest research report, the ?Postmenopausal Osteoporosis Drugs Industry Forecast? looks at past sales and reviews total world Postmenopausal Osteoporosis Drugs sales in 2024, providing a comprehensive analysis by region and market sector of projected Postmenopausal Osteoporosis Drugs sales for 2025 through 2031. With Postmenopausal Osteoporosis Drugs sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Postmenopausal Osteoporosis Drugs industry.

This Insight Report provides a comprehensive analysis of the global Postmenopausal Osteoporosis Drugs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Postmenopausal Osteoporosis Drugs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global Postmenopausal Osteoporosis Drugs market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Postmenopausal Osteoporosis Drugs and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Postmenopausal Osteoporosis Drugs.

This report presents a comprehensive overview, market shares, and growth opportunities of Postmenopausal Osteoporosis Drugs market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:

• Antiresorptive Medications
• Anabolic Medications

Segmentation by Application:

• Hospital
• Pharmacy
• Other

This report also splits the market by region:

• Americas
• United States
• Canada
• Mexico
• Brazil
• APAC
• China
• Japan
• Korea
• Southeast Asia
• India
• Australia
• Europe
• Germany
• France
• UK
• Italy
• Russia
• Middle East & Africa
• Egypt
• South Africa
• Israel
• Turkey
• GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.

• Eli Lilly
• Amgen
• Merck
• Novartis
• Allergan
• Amgen Astellas Biopharm
• Deltanoid Pharmaceuticals
• Noven
• Novo Nordisk
• Osteologix
• Pfizer
• PhytoHealth
• Radius Health
• Tarsa Therapeutics

Key Questions Addressed in this Report

What is the 10-year outlook for the global Postmenopausal Osteoporosis Drugs market?
What factors are driving Postmenopausal Osteoporosis Drugs market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Postmenopausal Osteoporosis Drugs market opportunities vary by end market size?
How does Postmenopausal Osteoporosis Drugs break out by Type, by Application?

Contents

1 SCOPE OF THE REPORT

1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

2.1 World Market Overview
  2.1.1 Global Postmenopausal Osteoporosis Drugs Annual Sales 2020-2031
  2.1.2 World Current & Future Analysis for Postmenopausal Osteoporosis Drugs by Geographic Region, 2020, 2024 & 2031
  2.1.3 World Current & Future Analysis for Postmenopausal Osteoporosis Drugs by Country/Region, 2020, 2024 & 2031
2.2 Postmenopausal Osteoporosis Drugs Segment by Type
  2.2.1 Antiresorptive Medications
  2.2.2 Anabolic Medications
2.3 Postmenopausal Osteoporosis Drugs Sales by Type
  2.3.1 Global Postmenopausal Osteoporosis Drugs Sales Market Share by Type (2020-2025)
  2.3.2 Global Postmenopausal Osteoporosis Drugs Revenue and Market Share by Type (2020-2025)
  2.3.3 Global Postmenopausal Osteoporosis Drugs Sale Price by Type (2020-2025)
2.4 Postmenopausal Osteoporosis Drugs Segment by Application
  2.4.1 Hospital
  2.4.2 Pharmacy
  2.4.3 Other
2.5 Postmenopausal Osteoporosis Drugs Sales by Application
  2.5.1 Global Postmenopausal Osteoporosis Drugs Sale Market Share by Application (2020-2025)
  2.5.2 Global Postmenopausal Osteoporosis Drugs Revenue and Market Share by Application (2020-2025)
  2.5.3 Global Postmenopausal Osteoporosis Drugs Sale Price by Application (2020-2025)

3 GLOBAL BY COMPANY

3.1 Global Postmenopausal Osteoporosis Drugs Breakdown Data by Company
  3.1.1 Global Postmenopausal Osteoporosis Drugs Annual Sales by Company (2020-2025)
  3.1.2 Global Postmenopausal Osteoporosis Drugs Sales Market Share by Company (2020-2025)
3.2 Global Postmenopausal Osteoporosis Drugs Annual Revenue by Company (2020-2025)
  3.2.1 Global Postmenopausal Osteoporosis Drugs Revenue by Company (2020-2025)
  3.2.2 Global Postmenopausal Osteoporosis Drugs Revenue Market Share by Company (2020-2025)
3.3 Global Postmenopausal Osteoporosis Drugs Sale Price by Company
3.4 Key Manufacturers Postmenopausal Osteoporosis Drugs Producing Area Distribution, Sales Area, Product Type
  3.4.1 Key Manufacturers Postmenopausal Osteoporosis Drugs Product Location Distribution
  3.4.2 Players Postmenopausal Osteoporosis Drugs Products Offered
3.5 Market Concentration Rate Analysis
  3.5.1 Competition Landscape Analysis
  3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy

4 WORLD HISTORIC REVIEW FOR POSTMENOPAUSAL OSTEOPOROSIS DRUGS BY GEOGRAPHIC REGION

4.1 World Historic Postmenopausal Osteoporosis Drugs Market Size by Geographic Region (2020-2025)
  4.1.1 Global Postmenopausal Osteoporosis Drugs Annual Sales by Geographic Region (2020-2025)
  4.1.2 Global Postmenopausal Osteoporosis Drugs Annual Revenue by Geographic Region (2020-2025)
4.2 World Historic Postmenopausal Osteoporosis Drugs Market Size by Country/Region (2020-2025)
  4.2.1 Global Postmenopausal Osteoporosis Drugs Annual Sales by Country/Region (2020-2025)
  4.2.2 Global Postmenopausal Osteoporosis Drugs Annual Revenue by Country/Region (2020-2025)
4.3 Americas Postmenopausal Osteoporosis Drugs Sales Growth
4.4 APAC Postmenopausal Osteoporosis Drugs Sales Growth
4.5 Europe Postmenopausal Osteoporosis Drugs Sales Growth
4.6 Middle East & Africa Postmenopausal Osteoporosis Drugs Sales Growth

5 AMERICAS

5.1 Americas Postmenopausal Osteoporosis Drugs Sales by Country
  5.1.1 Americas Postmenopausal Osteoporosis Drugs Sales by Country (2020-2025)
  5.1.2 Americas Postmenopausal Osteoporosis Drugs Revenue by Country (2020-2025)
5.2 Americas Postmenopausal Osteoporosis Drugs Sales by Type (2020-2025)
5.3 Americas Postmenopausal Osteoporosis Drugs Sales by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil

6 APAC

6.1 APAC Postmenopausal Osteoporosis Drugs Sales by Region
  6.1.1 APAC Postmenopausal Osteoporosis Drugs Sales by Region (2020-2025)
  6.1.2 APAC Postmenopausal Osteoporosis Drugs Revenue by Region (2020-2025)
6.2 APAC Postmenopausal Osteoporosis Drugs Sales by Type (2020-2025)
6.3 APAC Postmenopausal Osteoporosis Drugs Sales by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan

7 EUROPE

7.1 Europe Postmenopausal Osteoporosis Drugs by Country
  7.1.1 Europe Postmenopausal Osteoporosis Drugs Sales by Country (2020-2025)
  7.1.2 Europe Postmenopausal Osteoporosis Drugs Revenue by Country (2020-2025)
7.2 Europe Postmenopausal Osteoporosis Drugs Sales by Type (2020-2025)
7.3 Europe Postmenopausal Osteoporosis Drugs Sales by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia

8 MIDDLE EAST & AFRICA

8.1 Middle East & Africa Postmenopausal Osteoporosis Drugs by Country
  8.1.1 Middle East & Africa Postmenopausal Osteoporosis Drugs Sales by Country (2020-2025)
  8.1.2 Middle East & Africa Postmenopausal Osteoporosis Drugs Revenue by Country (2020-2025)
8.2 Middle East & Africa Postmenopausal Osteoporosis Drugs Sales by Type (2020-2025)
8.3 Middle East & Africa Postmenopausal Osteoporosis Drugs Sales by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends

10 MANUFACTURING COST STRUCTURE ANALYSIS

10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Postmenopausal Osteoporosis Drugs
10.3 Manufacturing Process Analysis of Postmenopausal Osteoporosis Drugs
10.4 Industry Chain Structure of Postmenopausal Osteoporosis Drugs

11 MARKETING, DISTRIBUTORS AND CUSTOMER

11.1 Sales Channel
  11.1.1 Direct Channels
  11.1.2 Indirect Channels
11.2 Postmenopausal Osteoporosis Drugs Distributors
11.3 Postmenopausal Osteoporosis Drugs Customer

12 WORLD FORECAST REVIEW FOR POSTMENOPAUSAL OSTEOPOROSIS DRUGS BY GEOGRAPHIC REGION

12.1 Global Postmenopausal Osteoporosis Drugs Market Size Forecast by Region
  12.1.1 Global Postmenopausal Osteoporosis Drugs Forecast by Region (2026-2031)
  12.1.2 Global Postmenopausal Osteoporosis Drugs Annual Revenue Forecast by Region (2026-2031)
12.2 Americas Forecast by Country (2026-2031)
12.3 APAC Forecast by Region (2026-2031)
12.4 Europe Forecast by Country (2026-2031)
12.5 Middle East & Africa Forecast by Country (2026-2031)
12.6 Global Postmenopausal Osteoporosis Drugs Forecast by Type (2026-2031)
12.7 Global Postmenopausal Osteoporosis Drugs Forecast by Application (2026-2031)

13 KEY PLAYERS ANALYSIS

13.1 Eli Lilly
  13.1.1 Eli Lilly Company Information
  13.1.2 Eli Lilly Postmenopausal Osteoporosis Drugs Product Portfolios and Specifications
  13.1.3 Eli Lilly Postmenopausal Osteoporosis Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
  13.1.4 Eli Lilly Main Business Overview
  13.1.5 Eli Lilly Latest Developments
13.2 Amgen
  13.2.1 Amgen Company Information
  13.2.2 Amgen Postmenopausal Osteoporosis Drugs Product Portfolios and Specifications
  13.2.3 Amgen Postmenopausal Osteoporosis Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
  13.2.4 Amgen Main Business Overview
  13.2.5 Amgen Latest Developments
13.3 Merck
  13.3.1 Merck Company Information
  13.3.2 Merck Postmenopausal Osteoporosis Drugs Product Portfolios and Specifications
  13.3.3 Merck Postmenopausal Osteoporosis Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
  13.3.4 Merck Main Business Overview
  13.3.5 Merck Latest Developments
13.4 Novartis
  13.4.1 Novartis Company Information
  13.4.2 Novartis Postmenopausal Osteoporosis Drugs Product Portfolios and Specifications
  13.4.3 Novartis Postmenopausal Osteoporosis Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
  13.4.4 Novartis Main Business Overview
  13.4.5 Novartis Latest Developments
13.5 Allergan
  13.5.1 Allergan Company Information
  13.5.2 Allergan Postmenopausal Osteoporosis Drugs Product Portfolios and Specifications
  13.5.3 Allergan Postmenopausal Osteoporosis Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
  13.5.4 Allergan Main Business Overview
  13.5.5 Allergan Latest Developments
13.6 Amgen Astellas Biopharm
  13.6.1 Amgen Astellas Biopharm Company Information
  13.6.2 Amgen Astellas Biopharm Postmenopausal Osteoporosis Drugs Product Portfolios and Specifications
  13.6.3 Amgen Astellas Biopharm Postmenopausal Osteoporosis Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
  13.6.4 Amgen Astellas Biopharm Main Business Overview
  13.6.5 Amgen Astellas Biopharm Latest Developments
13.7 Deltanoid Pharmaceuticals
  13.7.1 Deltanoid Pharmaceuticals Company Information
  13.7.2 Deltanoid Pharmaceuticals Postmenopausal Osteoporosis Drugs Product Portfolios and Specifications
  13.7.3 Deltanoid Pharmaceuticals Postmenopausal Osteoporosis Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
  13.7.4 Deltanoid Pharmaceuticals Main Business Overview
  13.7.5 Deltanoid Pharmaceuticals Latest Developments
13.8 Noven
  13.8.1 Noven Company Information
  13.8.2 Noven Postmenopausal Osteoporosis Drugs Product Portfolios and Specifications
  13.8.3 Noven Postmenopausal Osteoporosis Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
  13.8.4 Noven Main Business Overview
  13.8.5 Noven Latest Developments
13.9 Novo Nordisk
  13.9.1 Novo Nordisk Company Information
  13.9.2 Novo Nordisk Postmenopausal Osteoporosis Drugs Product Portfolios and Specifications
  13.9.3 Novo Nordisk Postmenopausal Osteoporosis Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
  13.9.4 Novo Nordisk Main Business Overview
  13.9.5 Novo Nordisk Latest Developments
13.10 Osteologix
  13.10.1 Osteologix Company Information
  13.10.2 Osteologix Postmenopausal Osteoporosis Drugs Product Portfolios and Specifications
  13.10.3 Osteologix Postmenopausal Osteoporosis Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
  13.10.4 Osteologix Main Business Overview
  13.10.5 Osteologix Latest Developments
13.11 Pfizer
  13.11.1 Pfizer Company Information
  13.11.2 Pfizer Postmenopausal Osteoporosis Drugs Product Portfolios and Specifications
  13.11.3 Pfizer Postmenopausal Osteoporosis Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
  13.11.4 Pfizer Main Business Overview
  13.11.5 Pfizer Latest Developments
13.12 PhytoHealth
  13.12.1 PhytoHealth Company Information
  13.12.2 PhytoHealth Postmenopausal Osteoporosis Drugs Product Portfolios and Specifications
  13.12.3 PhytoHealth Postmenopausal Osteoporosis Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
  13.12.4 PhytoHealth Main Business Overview
  13.12.5 PhytoHealth Latest Developments
13.13 Radius Health
  13.13.1 Radius Health Company Information
  13.13.2 Radius Health Postmenopausal Osteoporosis Drugs Product Portfolios and Specifications
  13.13.3 Radius Health Postmenopausal Osteoporosis Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
  13.13.4 Radius Health Main Business Overview
  13.13.5 Radius Health Latest Developments
13.14 Tarsa Therapeutics
  13.14.1 Tarsa Therapeutics Company Information
  13.14.2 Tarsa Therapeutics Postmenopausal Osteoporosis Drugs Product Portfolios and Specifications
  13.14.3 Tarsa Therapeutics Postmenopausal Osteoporosis Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
  13.14.4 Tarsa Therapeutics Main Business Overview
  13.14.5 Tarsa Therapeutics Latest Developments

14 RESEARCH FINDINGS AND CONCLUSION

List Of Tables

LIST OF TABLES

Table 1. Postmenopausal Osteoporosis Drugs Annual Sales CAGR by Geographic Region (2020, 2024 & 2031) & ($ millions)
Table 2. Postmenopausal Osteoporosis Drugs Annual Sales CAGR by Country/Region (2020, 2024 & 2031) & ($ millions)
Table 3. Major Players of Antiresorptive Medications
Table 4. Major Players of Anabolic Medications
Table 5. Global Postmenopausal Osteoporosis Drugs Sales by Type (2020-2025) & (K Pcs)
Table 6. Global Postmenopausal Osteoporosis Drugs Sales Market Share by Type (2020-2025)
Table 7. Global Postmenopausal Osteoporosis Drugs Revenue by Type (2020-2025) & ($ million)
Table 8. Global Postmenopausal Osteoporosis Drugs Revenue Market Share by Type (2020-2025)
Table 9. Global Postmenopausal Osteoporosis Drugs Sale Price by Type (2020-2025) & (USD/Pcs)
Table 10. Global Postmenopausal Osteoporosis Drugs Sale by Application (2020-2025) & (K Pcs)
Table 11. Global Postmenopausal Osteoporosis Drugs Sale Market Share by Application (2020-2025)
Table 12. Global Postmenopausal Osteoporosis Drugs Revenue by Application (2020-2025) & ($ million)
Table 13. Global Postmenopausal Osteoporosis Drugs Revenue Market Share by Application (2020-2025)
Table 14. Global Postmenopausal Osteoporosis Drugs Sale Price by Application (2020-2025) & (USD/Pcs)
Table 15. Global Postmenopausal Osteoporosis Drugs Sales by Company (2020-2025) & (K Pcs)
Table 16. Global Postmenopausal Osteoporosis Drugs Sales Market Share by Company (2020-2025)
Table 17. Global Postmenopausal Osteoporosis Drugs Revenue by Company (2020-2025) & ($ millions)
Table 18. Global Postmenopausal Osteoporosis Drugs Revenue Market Share by Company (2020-2025)
Table 19. Global Postmenopausal Osteoporosis Drugs Sale Price by Company (2020-2025) & (USD/Pcs)
Table 20. Key Manufacturers Postmenopausal Osteoporosis Drugs Producing Area Distribution and Sales Area
Table 21. Players Postmenopausal Osteoporosis Drugs Products Offered
Table 22. Postmenopausal Osteoporosis Drugs Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
Table 23. New Products and Potential Entrants
Table 24. Market M&A Activity & Strategy
Table 25. Global Postmenopausal Osteoporosis Drugs Sales by Geographic Region (2020-2025) & (K Pcs)
Table 26. Global Postmenopausal Osteoporosis Drugs Sales Market Share Geographic Region (2020-2025)
Table 27. Global Postmenopausal Osteoporosis Drugs Revenue by Geographic Region (2020-2025) & ($ millions)
Table 28. Global Postmenopausal Osteoporosis Drugs Revenue Market Share by Geographic Region (2020-2025)
Table 29. Global Postmenopausal Osteoporosis Drugs Sales by Country/Region (2020-2025) & (K Pcs)
Table 30. Global Postmenopausal Osteoporosis Drugs Sales Market Share by Country/Region (2020-2025)
Table 31. Global Postmenopausal Osteoporosis Drugs Revenue by Country/Region (2020-2025) & ($ millions)
Table 32. Global Postmenopausal Osteoporosis Drugs Revenue Market Share by Country/Region (2020-2025)
Table 33. Americas Postmenopausal Osteoporosis Drugs Sales by Country (2020-2025) & (K Pcs)
Table 34. Americas Postmenopausal Osteoporosis Drugs Sales Market Share by Country (2020-2025)
Table 35. Americas Postmenopausal Osteoporosis Drugs Revenue by Country (2020-2025) & ($ millions)
Table 36. Americas Postmenopausal Osteoporosis Drugs Sales by Type (2020-2025) & (K Pcs)
Table 37. Americas Postmenopausal Osteoporosis Drugs Sales by Application (2020-2025) & (K Pcs)
Table 38. APAC Postmenopausal Osteoporosis Drugs Sales by Region (2020-2025) & (K Pcs)
Table 39. APAC Postmenopausal Osteoporosis Drugs Sales Market Share by Region (2020-2025)
Table 40. APAC Postmenopausal Osteoporosis Drugs Revenue by Region (2020-2025) & ($ millions)
Table 41. APAC Postmenopausal Osteoporosis Drugs Sales by Type (2020-2025) & (K Pcs)
Table 42. APAC Postmenopausal Osteoporosis Drugs Sales by Application (2020-2025) & (K Pcs)
Table 43. Europe Postmenopausal Osteoporosis Drugs Sales by Country (2020-2025) & (K Pcs)
Table 44. Europe Postmenopausal Osteoporosis Drugs Revenue by Country (2020-2025) & ($ millions)
Table 45. Europe Postmenopausal Osteoporosis Drugs Sales by Type (2020-2025) & (K Pcs)
Table 46. Europe Postmenopausal Osteoporosis Drugs Sales by Application (2020-2025) & (K Pcs)
Table 47. Middle East & Africa Postmenopausal Osteoporosis Drugs Sales by Country (2020-2025) & (K Pcs)
Table 48. Middle East & Africa Postmenopausal Osteoporosis Drugs Revenue Market Share by Country (2020-2025)
Table 49. Middle East & Africa Postmenopausal Osteoporosis Drugs Sales by Type (2020-2025) & (K Pcs)
Table 50. Middle East & Africa Postmenopausal Osteoporosis Drugs Sales by Application (2020-2025) & (K Pcs)
Table 51. Key Market Drivers & Growth Opportunities of Postmenopausal Osteoporosis Drugs
Table 52. Key Market Challenges & Risks of Postmenopausal Osteoporosis Drugs
Table 53. Key Industry Trends of Postmenopausal Osteoporosis Drugs
Table 54. Postmenopausal Osteoporosis Drugs Raw Material
Table 55. Key Suppliers of Raw Materials
Table 56. Postmenopausal Osteoporosis Drugs Distributors List
Table 57. Postmenopausal Osteoporosis Drugs Customer List
Table 58. Global Postmenopausal Osteoporosis Drugs Sales Forecast by Region (2026-2031) & (K Pcs)
Table 59. Global Postmenopausal Osteoporosis Drugs Revenue Forecast by Region (2026-2031) & ($ millions)
Table 60. Americas Postmenopausal Osteoporosis Drugs Sales Forecast by Country (2026-2031) & (K Pcs)
Table 61. Americas Postmenopausal Osteoporosis Drugs Annual Revenue Forecast by Country (2026-2031) & ($ millions)
Table 62. APAC Postmenopausal Osteoporosis Drugs Sales Forecast by Region (2026-2031) & (K Pcs)
Table 63. APAC Postmenopausal Osteoporosis Drugs Annual Revenue Forecast by Region (2026-2031) & ($ millions)
Table 64. Europe Postmenopausal Osteoporosis Drugs Sales Forecast by Country (2026-2031) & (K Pcs)
Table 65. Europe Postmenopausal Osteoporosis Drugs Revenue Forecast by Country (2026-2031) & ($ millions)
Table 66. Middle East & Africa Postmenopausal Osteoporosis Drugs Sales Forecast by Country (2026-2031) & (K Pcs)
Table 67. Middle East & Africa Postmenopausal Osteoporosis Drugs Revenue Forecast by Country (2026-2031) & ($ millions)
Table 68. Global Postmenopausal Osteoporosis Drugs Sales Forecast by Type (2026-2031) & (K Pcs)
Table 69. Global Postmenopausal Osteoporosis Drugs Revenue Forecast by Type (2026-2031) & ($ millions)
Table 70. Global Postmenopausal Osteoporosis Drugs Sales Forecast by Application (2026-2031) & (K Pcs)
Table 71. Global Postmenopausal Osteoporosis Drugs Revenue Forecast by Application (2026-2031) & ($ millions)
Table 72. Eli Lilly Basic Information, Postmenopausal Osteoporosis Drugs Manufacturing Base, Sales Area and Its Competitors
Table 73. Eli Lilly Postmenopausal Osteoporosis Drugs Product Portfolios and Specifications
Table 74. Eli Lilly Postmenopausal Osteoporosis Drugs Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 75. Eli Lilly Main Business
Table 76. Eli Lilly Latest Developments
Table 77. Amgen Basic Information, Postmenopausal Osteoporosis Drugs Manufacturing Base, Sales Area and Its Competitors
Table 78. Amgen Postmenopausal Osteoporosis Drugs Product Portfolios and Specifications
Table 79. Amgen Postmenopausal Osteoporosis Drugs Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 80. Amgen Main Business
Table 81. Amgen Latest Developments
Table 82. Merck Basic Information, Postmenopausal Osteoporosis Drugs Manufacturing Base, Sales Area and Its Competitors
Table 83. Merck Postmenopausal Osteoporosis Drugs Product Portfolios and Specifications
Table 84. Merck Postmenopausal Osteoporosis Drugs Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 85. Merck Main Business
Table 86. Merck Latest Developments
Table 87. Novartis Basic Information, Postmenopausal Osteoporosis Drugs Manufacturing Base, Sales Area and Its Competitors
Table 88. Novartis Postmenopausal Osteoporosis Drugs Product Portfolios and Specifications
Table 89. Novartis Postmenopausal Osteoporosis Drugs Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 90. Novartis Main Business
Table 91. Novartis Latest Developments
Table 92. Allergan Basic Information, Postmenopausal Osteoporosis Drugs Manufacturing Base, Sales Area and Its Competitors
Table 93. Allergan Postmenopausal Osteoporosis Drugs Product Portfolios and Specifications
Table 94. Allergan Postmenopausal Osteoporosis Drugs Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 95. Allergan Main Business
Table 96. Allergan Latest Developments
Table 97. Amgen Astellas Biopharm Basic Information, Postmenopausal Osteoporosis Drugs Manufacturing Base, Sales Area and Its Competitors
Table 98. Amgen Astellas Biopharm Postmenopausal Osteoporosis Drugs Product Portfolios and Specifications
Table 99. Amgen Astellas Biopharm Postmenopausal Osteoporosis Drugs Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 100. Amgen Astellas Biopharm Main Business
Table 101. Amgen Astellas Biopharm Latest Developments
Table 102. Deltanoid Pharmaceuticals Basic Information, Postmenopausal Osteoporosis Drugs Manufacturing Base, Sales Area and Its Competitors
Table 103. Deltanoid Pharmaceuticals Postmenopausal Osteoporosis Drugs Product Portfolios and Specifications
Table 104. Deltanoid Pharmaceuticals Postmenopausal Osteoporosis Drugs Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 105. Deltanoid Pharmaceuticals Main Business
Table 106. Deltanoid Pharmaceuticals Latest Developments
Table 107. Noven Basic Information, Postmenopausal Osteoporosis Drugs Manufacturing Base, Sales Area and Its Competitors
Table 108. Noven Postmenopausal Osteoporosis Drugs Product Portfolios and Specifications
Table 109. Noven Postmenopausal Osteoporosis Drugs Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 110. Noven Main Business
Table 111. Noven Latest Developments
Table 112. Novo Nordisk Basic Information, Postmenopausal Osteoporosis Drugs Manufacturing Base, Sales Area and Its Competitors
Table 113. Novo Nordisk Postmenopausal Osteoporosis Drugs Product Portfolios and Specifications
Table 114. Novo Nordisk Postmenopausal Osteoporosis Drugs Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 115. Novo Nordisk Main Business
Table 116. Novo Nordisk Latest Developments
Table 117. Osteologix Basic Information, Postmenopausal Osteoporosis Drugs Manufacturing Base, Sales Area and Its Competitors
Table 118. Osteologix Postmenopausal Osteoporosis Drugs Product Portfolios and Specifications
Table 119. Osteologix Postmenopausal Osteoporosis Drugs Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 120. Osteologix Main Business
Table 121. Osteologix Latest Developments
Table 122. Pfizer Basic Information, Postmenopausal Osteoporosis Drugs Manufacturing Base, Sales Area and Its Competitors
Table 123. Pfizer Postmenopausal Osteoporosis Drugs Product Portfolios and Specifications
Table 124. Pfizer Postmenopausal Osteoporosis Drugs Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 125. Pfizer Main Business
Table 126. Pfizer Latest Developments
Table 127. PhytoHealth Basic Information, Postmenopausal Osteoporosis Drugs Manufacturing Base, Sales Area and Its Competitors
Table 128. PhytoHealth Postmenopausal Osteoporosis Drugs Product Portfolios and Specifications
Table 129. PhytoHealth Postmenopausal Osteoporosis Drugs Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 130. PhytoHealth Main Business
Table 131. PhytoHealth Latest Developments
Table 132. Radius Health Basic Information, Postmenopausal Osteoporosis Drugs Manufacturing Base, Sales Area and Its Competitors
Table 133. Radius Health Postmenopausal Osteoporosis Drugs Product Portfolios and Specifications
Table 134. Radius Health Postmenopausal Osteoporosis Drugs Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 135. Radius Health Main Business
Table 136. Radius Health Latest Developments
Table 137. Tarsa Therapeutics Basic Information, Postmenopausal Osteoporosis Drugs Manufacturing Base, Sales Area and Its Competitors
Table 138. Tarsa Therapeutics Postmenopausal Osteoporosis Drugs Product Portfolios and Specifications
Table 139. Tarsa Therapeutics Postmenopausal Osteoporosis Drugs Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 140. Tarsa Therapeutics Main Business
Table 141. Tarsa Therapeutics Latest Developments

List Of Figures

LIST OF FIGURES

Figure 1. Picture of Postmenopausal Osteoporosis Drugs
Figure 2. Postmenopausal Osteoporosis Drugs Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Postmenopausal Osteoporosis Drugs Sales Growth Rate 2020-2031 (K Pcs)
Figure 7. Global Postmenopausal Osteoporosis Drugs Revenue Growth Rate 2020-2031 ($ millions)
Figure 8. Postmenopausal Osteoporosis Drugs Sales by Geographic Region (2020, 2024 & 2031) & ($ millions)
Figure 9. Postmenopausal Osteoporosis Drugs Sales Market Share by Country/Region (2024)
Figure 10. Postmenopausal Osteoporosis Drugs Sales Market Share by Country/Region (2020, 2024 & 2031)
Figure 11. Product Picture of Antiresorptive Medications
Figure 12. Product Picture of Anabolic Medications
Figure 13. Global Postmenopausal Osteoporosis Drugs Sales Market Share by Type in 2025
Figure 14. Global Postmenopausal Osteoporosis Drugs Revenue Market Share by Type (2020-2025)
Figure 15. Postmenopausal Osteoporosis Drugs Consumed in Hospital
Figure 16. Global Postmenopausal Osteoporosis Drugs Market: Hospital (2020-2025) & (K Pcs)
Figure 17. Postmenopausal Osteoporosis Drugs Consumed in Pharmacy
Figure 18. Global Postmenopausal Osteoporosis Drugs Market: Pharmacy (2020-2025) & (K Pcs)
Figure 19. Postmenopausal Osteoporosis Drugs Consumed in Other
Figure 20. Global Postmenopausal Osteoporosis Drugs Market: Other (2020-2025) & (K Pcs)
Figure 21. Global Postmenopausal Osteoporosis Drugs Sale Market Share by Application (2024)
Figure 22. Global Postmenopausal Osteoporosis Drugs Revenue Market Share by Application in 2025
Figure 23. Postmenopausal Osteoporosis Drugs Sales by Company in 2025 (K Pcs)
Figure 24. Global Postmenopausal Osteoporosis Drugs Sales Market Share by Company in 2025
Figure 25. Postmenopausal Osteoporosis Drugs Revenue by Company in 2025 ($ millions)
Figure 26. Global Postmenopausal Osteoporosis Drugs Revenue Market Share by Company in 2025
Figure 27. Global Postmenopausal Osteoporosis Drugs Sales Market Share by Geographic Region (2020-2025)
Figure 28. Global Postmenopausal Osteoporosis Drugs Revenue Market Share by Geographic Region in 2025
Figure 29. Americas Postmenopausal Osteoporosis Drugs Sales 2020-2025 (K Pcs)
Figure 30. Americas Postmenopausal Osteoporosis Drugs Revenue 2020-2025 ($ millions)
Figure 31. APAC Postmenopausal Osteoporosis Drugs Sales 2020-2025 (K Pcs)
Figure 32. APAC Postmenopausal Osteoporosis Drugs Revenue 2020-2025 ($ millions)
Figure 33. Europe Postmenopausal Osteoporosis Drugs Sales 2020-2025 (K Pcs)
Figure 34. Europe Postmenopausal Osteoporosis Drugs Revenue 2020-2025 ($ millions)
Figure 35. Middle East & Africa Postmenopausal Osteoporosis Drugs Sales 2020-2025 (K Pcs)
Figure 36. Middle East & Africa Postmenopausal Osteoporosis Drugs Revenue 2020-2025 ($ millions)
Figure 37. Americas Postmenopausal Osteoporosis Drugs Sales Market Share by Country in 2025
Figure 38. Americas Postmenopausal Osteoporosis Drugs Revenue Market Share by Country (2020-2025)
Figure 39. Americas Postmenopausal Osteoporosis Drugs Sales Market Share by Type (2020-2025)
Figure 40. Americas Postmenopausal Osteoporosis Drugs Sales Market Share by Application (2020-2025)
Figure 41. United States Postmenopausal Osteoporosis Drugs Revenue Growth 2020-2025 ($ millions)
Figure 42. Canada Postmenopausal Osteoporosis Drugs Revenue Growth 2020-2025 ($ millions)
Figure 43. Mexico Postmenopausal Osteoporosis Drugs Revenue Growth 2020-2025 ($ millions)
Figure 44. Brazil Postmenopausal Osteoporosis Drugs Revenue Growth 2020-2025 ($ millions)
Figure 45. APAC Postmenopausal Osteoporosis Drugs Sales Market Share by Region in 2025
Figure 46. APAC Postmenopausal Osteoporosis Drugs Revenue Market Share by Region (2020-2025)
Figure 47. APAC Postmenopausal Osteoporosis Drugs Sales Market Share by Type (2020-2025)
Figure 48. APAC Postmenopausal Osteoporosis Drugs Sales Market Share by Application (2020-2025)
Figure 49. China Postmenopausal Osteoporosis Drugs Revenue Growth 2020-2025 ($ millions)
Figure 50. Japan Postmenopausal Osteoporosis Drugs Revenue Growth 2020-2025 ($ millions)
Figure 51. South Korea Postmenopausal Osteoporosis Drugs Revenue Growth 2020-2025 ($ millions)
Figure 52. Southeast Asia Postmenopausal Osteoporosis Drugs Revenue Growth 2020-2025 ($ millions)
Figure 53. India Postmenopausal Osteoporosis Drugs Revenue Growth 2020-2025 ($ millions)
Figure 54. Australia Postmenopausal Osteoporosis Drugs Revenue Growth 2020-2025 ($ millions)
Figure 55. China Taiwan Postmenopausal Osteoporosis Drugs Revenue Growth 2020-2025 ($ millions)
Figure 56. Europe Postmenopausal Osteoporosis Drugs Sales Market Share by Country in 2025
Figure 57. Europe Postmenopausal Osteoporosis Drugs Revenue Market Share by Country (2020-2025)
Figure 58. Europe Postmenopausal Osteoporosis Drugs Sales Market Share by Type (2020-2025)
Figure 59. Europe Postmenopausal Osteoporosis Drugs Sales Market Share by Application (2020-2025)
Figure 60. Germany Postmenopausal Osteoporosis Drugs Revenue Growth 2020-2025 ($ millions)
Figure 61. France Postmenopausal Osteoporosis Drugs Revenue Growth 2020-2025 ($ millions)
Figure 62. UK Postmenopausal Osteoporosis Drugs Revenue Growth 2020-2025 ($ millions)
Figure 63. Italy Postmenopausal Osteoporosis Drugs Revenue Growth 2020-2025 ($ millions)
Figure 64. Russia Postmenopausal Osteoporosis Drugs Revenue Growth 2020-2025 ($ millions)
Figure 65. Middle East & Africa Postmenopausal Osteoporosis Drugs Sales Market Share by Country (2020-2025)
Figure 66. Middle East & Africa Postmenopausal Osteoporosis Drugs Sales Market Share by Type (2020-2025)
Figure 67. Middle East & Africa Postmenopausal Osteoporosis Drugs Sales Market Share by Application (2020-2025)
Figure 68. Egypt Postmenopausal Osteoporosis Drugs Revenue Growth 2020-2025 ($ millions)
Figure 69. South Africa Postmenopausal Osteoporosis Drugs Revenue Growth 2020-2025 ($ millions)
Figure 70. Israel Postmenopausal Osteoporosis Drugs Revenue Growth 2020-2025 ($ millions)
Figure 71. Turkey Postmenopausal Osteoporosis Drugs Revenue Growth 2020-2025 ($ millions)
Figure 72. GCC Countries Postmenopausal Osteoporosis Drugs Revenue Growth 2020-2025 ($ millions)
Figure 73. Manufacturing Cost Structure Analysis of Postmenopausal Osteoporosis Drugs in 2025
Figure 74. Manufacturing Process Analysis of Postmenopausal Osteoporosis Drugs
Figure 75. Industry Chain Structure of Postmenopausal Osteoporosis Drugs
Figure 76. Channels of Distribution
Figure 77. Global Postmenopausal Osteoporosis Drugs Sales Market Forecast by Region (2026-2031)
Figure 78. Global Postmenopausal Osteoporosis Drugs Revenue Market Share Forecast by Region (2026-2031)
Figure 79. Global Postmenopausal Osteoporosis Drugs Sales Market Share Forecast by Type (2026-2031)
Figure 80. Global Postmenopausal Osteoporosis Drugs Revenue Market Share Forecast by Type (2026-2031)
Figure 81. Global Postmenopausal Osteoporosis Drugs Sales Market Share Forecast by Application (2026-2031)
Figure 82. Global Postmenopausal Osteoporosis Drugs Revenue Market Share Forecast by Application (2026-2031)